Q4 EPS Estimate for Merit Medical Systems Reduced by Analyst

Merit Medical Systems, Inc. (NASDAQ:MMSI - Free Report) - Zacks Research reduced their Q4 2024 earnings per share estimates for Merit Medical Systems in a research note issued on Wednesday, November 20th. Zacks Research analyst I. Bandyopadhyay now expects that the medical instruments supplier will post earnings of $0.81 per share for the quarter, down from their prior forecast of $0.83. The consensus estimate for Merit Medical Systems' current full-year earnings is $3.36 per share. Zacks Research also issued estimates for Merit Medical Systems' Q3 2026 earnings at $1.07 EPS.

Merit Medical Systems (NASDAQ:MMSI - Get Free Report) last released its quarterly earnings data on Wednesday, October 30th. The medical instruments supplier reported $0.86 earnings per share for the quarter, beating analysts' consensus estimates of $0.80 by $0.06. The business had revenue of $339.85 million during the quarter, compared to analyst estimates of $334.60 million. Merit Medical Systems had a return on equity of 15.61% and a net margin of 9.05%. The company's revenue was up 7.8% on a year-over-year basis. During the same quarter last year, the business posted $0.75 EPS.

Other equities research analysts have also recently issued reports about the company. Needham & Company LLC restated a "buy" rating and set a $109.00 target price on shares of Merit Medical Systems in a research report on Thursday, October 31st. Barrington Research reaffirmed an "outperform" rating and set a $114.00 price objective on shares of Merit Medical Systems in a research note on Thursday, October 31st. Bank of America lifted their price target on Merit Medical Systems from $92.00 to $103.00 and gave the stock a "neutral" rating in a report on Monday, September 16th. Wells Fargo & Company upped their price objective on Merit Medical Systems from $85.00 to $103.00 and gave the company an "equal weight" rating in a report on Monday, September 16th. Finally, StockNews.com lowered shares of Merit Medical Systems from a "buy" rating to a "hold" rating in a research note on Sunday, November 3rd. Three analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $103.36.

Merit Medical Systems Stock Performance

Merit Medical Systems stock traded down $0.41 during mid-day trading on Monday, hitting $104.92. The company had a trading volume of 565,303 shares, compared to its average volume of 439,359. The company has a market capitalization of $6.11 billion, a price-to-earnings ratio of 51.63, a P/E/G ratio of 2.62 and a beta of 0.89. The company has a current ratio of 5.36, a quick ratio of 3.82 and a debt-to-equity ratio of 0.57. The company's fifty day moving average is $98.59 and its 200-day moving average is $90.99. Merit Medical Systems has a 12-month low of $65.46 and a 12-month high of $106.87.

Insider Buying and Selling at Merit Medical Systems

In related news, CFO Raul Jr. Parra sold 29,646 shares of the firm's stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $98.02, for a total transaction of $2,905,900.92. Following the transaction, the chief financial officer now owns 16,361 shares in the company, valued at $1,603,705.22. This trade represents a 64.44 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director F. Ann Millner sold 12,500 shares of Merit Medical Systems stock in a transaction that occurred on Friday, November 15th. The stock was sold at an average price of $101.55, for a total value of $1,269,375.00. Following the transaction, the director now directly owns 32,391 shares in the company, valued at approximately $3,289,306.05. This trade represents a 27.85 % decrease in their position. The disclosure for this sale can be found here. 3.70% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Opal Wealth Advisors LLC acquired a new position in Merit Medical Systems during the 2nd quarter worth approximately $29,000. DekaBank Deutsche Girozentrale acquired a new stake in shares of Merit Medical Systems in the first quarter valued at approximately $44,000. USA Financial Formulas acquired a new position in shares of Merit Medical Systems in the third quarter worth $59,000. GAMMA Investing LLC increased its position in Merit Medical Systems by 142.3% during the 2nd quarter. GAMMA Investing LLC now owns 831 shares of the medical instruments supplier's stock worth $71,000 after purchasing an additional 488 shares in the last quarter. Finally, National Bank of Canada FI acquired a new position in shares of Merit Medical Systems in the second quarter valued at approximately $77,000. Institutional investors and hedge funds own 99.66% of the company's stock.

About Merit Medical Systems

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.